Table 4.
Review of Literature ever reported for PEACs
| Study | No. Of Cases | Sex/Age (y) | Size (mm)/Site | Smoking | Immunohistochemical Combination | Follow-up (mo) |
|---|---|---|---|---|---|---|
| Inamura et al. [2] | 7 | 6, M; 1, F/NA | 17-50//3, RLL; 2, LUL; 1, LLL; 1, RUL | 7, Yes | CK7/CK20/TTF-1/CDX2/SPA/Napsin A/MUC2 | 12-60/5, A; 2, D |
| Yousem [8] | 6 | 1, M; 5, F/57-74 | 15-70/5, RUL; 1, LLL | 6, Yes | CK7/CK20/TTF-1/CDX2/SPA/MUC1/MUC2/MUC5A | 2-26/3, A; 3, D |
| Maeda et al. [3] | 1 | M/69 | 25/RLL | NA | CK7/CK20/TTF-1 | NA |
| Li HC et al. [10] | 1 | F/51 | 33/LLL | Yes | CK7/CK20/TTF-1/CDX2 | 10/A |
| Hatanaka et al. [9] | 1 | F/51 | 30/LLL and 10/RUL | No | CK7/CK20/TTF-1/CDX2/Napsin A/MUC2/MUC5AC | 48/A |
| Lin D et al. [22] | 1 | F/61 | 50/RML | No | CK7/CK20/TTF-1/Villin | 6/A |
M, male; F, female; A, alive; D, dead; CK, cytokeratin; LLL, left lower lobe; RLL, right lower lobe; LUL, left upper lobe; RUL, right upper lobe; RML, right middle lobe; NA, not avaiable.